Adalat LA 30

  • Name:

    Adalat LA 30

  • Company:
    info
  • Active Ingredients:

    Nifedipine

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 18/04/17

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 8/7/2016
print

Print ViewKeyword Search SmPC

Bayer Limited

Bayer Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Adalat LA 20 Active Ingredients Nifedipine
Medicine Name Adalat LA 30 Active Ingredients Nifedipine
Medicine Name Adalat LA 60 Active Ingredients Nifedipine
Medicine Name Alka Seltzer Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin), Citric Acid, Sodium Hydrogen Carbonate
Medicine Name Androcur 100 Active Ingredients Cyproterone Acetate
Medicine Name Angeliq 1 mg / 2 mg film-coated tablets Active Ingredients Drospirenone, Estradiol Hemihydrate
Medicine Name Aspirin 300mg Effervescent Tablets Active Ingredients Acetylsalicylic acid (Aspirin)
Medicine Name Avelox 400mg Film-coatedTablets Active Ingredients Moxifloxacin hydrochloride
Medicine Name Avelox 400mg/250ml Solution for Infusion Active Ingredients Moxifloxacin hydrochloride
Medicine Name Bepantiseptic First Aid Cream Active Ingredients Chlorhexidine digluconate, Phenol
Medicine Name Betaferon 250 microgram/ml, powder and solvent for solution for injection Active Ingredients Interferon beta-1b
Medicine Name Canesten 200mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten 500mg Pessary Active Ingredients Clotrimazole
Medicine Name Canesten Combi Pessary and Cream Active Ingredients Clotrimazole
Medicine Name Canesten Cream Active Ingredients Clotrimazole
Medicine Name Canesten Duopak Active Ingredients Clotrimazole
Medicine Name Canesten HC Cream Active Ingredients Clotrimazole, Hydrocortisone
Medicine Name Canesten Soft Vaginal Capsule Combi Active Ingredients Clotrimazole
Medicine Name Canesten Thrush Cream Active Ingredients Clotrimazole
Medicine Name Ciproxin 250mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin 500mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin 750mg Film-coated Tablets Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Ciproxin Solution for Infusion 2mg/ml, 200ml Active Ingredients Ciprofloxacin
Medicine Name Clarityn 10 mg Tablets Active Ingredients Loratadine
Medicine Name Cystopurin 3g Granules for Oral Solution Active Ingredients Potassium Citrate
1 - 0 of 74 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18 April 2017 PIL

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 18 April 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 12 August 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 11 July 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 8 July 2016 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In Section 4.6 Fertility, pregnancy and lactation

Acute pulmonary oedema has been observed when calcium channel blockers, among others nifedipine, have been used as a tocolytic agent during pregnancy (see section 4.8), especially in cases of multiple pregnancy (twins or more), with the intravenous route and/or concomitant use of beta-2 agonists. -was added.

In Section 4.8 Undesirable effects

Pulmonary oedema* -was added as a side effect. under the frequency 'Not Known', with the following condition* :
*cases have been reported when used as tocolytic during pregnancy (see section 4.6) -was added


10. Date of Revision of the Text
June 2016 -was added

Updated on 8 July 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 9 January 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 9 January 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 was updated to include HPRA adverse effect reporting text

Updated on 11 March 2014 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2 Posology and method of administration

Additional information on special populations

Elderly (>65)Geriatric patients

 

 

4.3          Contraindications

The safety of Adalat LA during pregnancy or in nursing mothers has not been established (see sections 4.4, 4.6 and 5.3).

 

Adalat LA must not be administered during pregnancy or to nursing mothers.

 

Adalat LA must not be used in cases of cardiogenic shock, clinically significant aortic stenosis, unstable angina pectoris, or during or within one month of a myocardial infarction.

4.4    Special warnings and precautions for use

Care must be exercised in patients with very low blood pressure (severe hypotension with systolic pressure less than 90 mm HG), in cases of manifest heart failure and in the case of severe aortic stenosis.

 

Nifedipine should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine. Nifedipine should be reserved for women with severe hypertension who are unresponsive to standard therapy (see section 4.6).

 

Nifedipine is not recommended for use during breastfeeding because nifedipine has been reported to be excreted in human milk and the effects of oral absorption of small amounts of nifedipine are not known (see section 4.6).

 

 

There are no safety and efficacy data from well-controlled studies in pregnant women (See Section 4.6).

 

Animal studies have shown a variety of embryotoxic, placentotoxic and fetotoxic effects (see Section 5.3) when administered during and after the period of organogenesis.

 

Whilst nifedipine is contra-indicated in pregnancy, particular care must be exercised when administering nifedipine in combination with i.v. magnesium sulphate to pregnant women.

 

Careful monitoring of blood pressure must be exercised, also when administered    nifedipine with i.v. magnesium sulfate, owing to the possibility of an excessive fall in blood pressure which could harm both mother and fetus.

 

In single cases obstructive symptoms have been described without known history of gastrointestinal disorders.

 

 

Nifedipine is metabolised via the cytochrome P450 3A4 system. Drugs that are known to either inhibit or to induce this enzyme system may therefore alter the first pass or the clearance of nifedipine (See Section 4.5)

 

Drugs, which are inhibitors of the cytochrome P450 3 A4 system, and which may therefore lead to increased plasma concentrations of nifedipine include, for example:

 

-macrolide antibiotics (e.g., erythromycin)

-anti-HIV protease inhibitors (e.g., ritonavir)

-azole antimycotics (e.g., ketoconazole)

-the antidepressants, nefazodone and fluoxetine

-quinupristin/dalfopristin

-valproic acid

-cimetidine

 

Upon co-administration with these drugs, the blood pressure should be monitored and, if necessary, a reduction of the nifedipine dose should be considered.

 

For use in special populations see section 4.2.

 

4.5   Interaction with other medicinal products and other forms of interactions

Macrolide antibiotics (e.g., erythromycin):

No interaction studies have been carried out between nifedipine and macrolide antibiotics.  Certain macrolide antibiotics are known to inhibit the cytochrome P450 3A4 mediated metabolism of other drugs. Therefore the potential for an increase of nifedipine plasma concentrations upon co-administration of both drugs cannot be excluded (see Section 4.4).

 

Anti-HIV protease inhibitors (e.g., ritonavir):

A clinical study investigating the potential of a drug interaction between nifedipine and certain anti-HIV protease inhibitors has not yet been performed. Drugs of this class are known to inhibit the cytochrome P450 3A4 system. In addition, dDrugs of this class have been shown to inhibit in vitro the cytochrome P450 3A4 mediated metabolism of nifedipine. When administered together with nifedipine, a substantial increase in plasma concentrations of nifedipine due to a decreased first pass metabolism and a decreased elimination cannot be excluded (see Section 4.4).

Azole anti-mycotics (e.g., ketoconazole):

A formal interaction study investigating the potential of a drug interaction between nifedipine and certain azole anti-mycotics has not yet been performed. Drugs of this class are known to inhibit the cytochrome P450 3A4 system. When administered orally together with nifedipine, a substantial increase in systemic bioavailability of nifedipine due to a decreased first pass metabolism cannot be excluded (see Section 4.4).

Fluoxetine:

A clinical study investigating the potential of a drug interaction between nifedipine and fluoxetine has not yet been performed. Fluoxetine has been shown to inhibit in vitro the cytochrome P450 3A4 mediated metabolism of nifedipine. Therefore an increase of nifedipine plasma concentrations upon co-administration of both drugs cannot be excluded (see Section 4.4).

 

Nefazodone:

A clinical study investigating the potential of a drug interaction between nifedipine and nefazodone has not yet been performed. Nefazodone is known to inhibit the cytochrome P450 3 A4 mediated metabolism of other drugs. Therefore an increase in nifedipine plasma concentrations upon co-administration of both drugs cannot be excluded (see Section 4.4).

 

Quinupristin/dalfopristin

Simultaneous administration of quinupristin / dalfopristin and nifedipine, may lead to increased plasma concentrations of nifedipine (see Section 4.4).

 

Valproic acid:

No formal studies have been performed to investigate the potential interaction between nifedipine and valproic acid. As valproic acid has been shown to increase the plasma concentrations of the structurally similar calcium channel blocker, nimodipine, due to enzyme inhibition, an increase in nifedipine plasma concentrations and hence an increase in efficacy cannot be excluded (see Section 4.4).

Effects of nifedipine on other drugs

Blood pressure lowering drugs

4.6          Fertility, pregnancy and lactation

 

Pregnancy

Adalat LA is contra-indicated during pregnancy.

Nifedipine should not be used during pregnancy unless the clinical condition of the woman requires treatment with nifedipine. Nifedipine should be reserved for women with severe hypertension who are unresponsive to standard therapy (see section 4.4).

 

The safety of Adalat LA for use in human pregnancy has not been established.  Evaluation of experimental animal studies has shown reproductive toxicity consisting of embryotoxicity and teratogenic effects at maternally toxic doses.

 

There are no adequate and well controlled studies in pregnant women.

 

 

The available information is inadequate to rule out adverse drug effects on the unborn and newborn child.

 

In animal studies nifedipine has been shown to produce embryotoxicity, fetotoxicity and teratogenicity (see section 5.3).

 

 

 

From the clinical evidence available a specific prenatal risk has not been identified. Although an increase in perinatal asphyxia, caesarean delivery as well as prematurity and intrauterine growth retardation has been reported. It is unclear whether these reports are due to the underlying hypertension, its treatment or to a specific drug effect.

 

 

Breast-feedingLactation

Adalat Retard 20mg is contra-indicated in breastfeeding. Nifedipine passes into the breast milk. As there is no experience of possible effects on infants, breastfeeding should first be stopped if nifedipine treatment becomes necessary during the breastfeeding period.

Nifedipine is excreted in the breast milk. The nifedipine concentration in the milk is almost comparable with mother serum concentration. For immediate release formulations, it is proposed to delay breastfeeding or milk expression for 3 to 4 hours after drug administration to decrease the nifedipine exposure to the infant (see section 4.4).

In- vitro fertilisation

Fertility

4.8          Undesirable effects

System Organ Class

(MedDRA)

Common

Uncommon

Rare

Not known

 

                                        Oedema (incl. peripheral oedema)

                                       Vasodilation

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the online reporting option (preferred method) accessible from the IMB homepage (www.imb.ie). A downloadable report form is also accessible from the IMB website, which may be completed manually and submitted to the IMB via ‘freepost’ (see details below). Alternatively, the traditional post-paid ‘yellow card’ option may also be used.

 

Ireland

IMB Pharmacovigilance

Earlsfort Terrace

IRL - Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.imb.ie

e-mail: imbpharmacovigilance@imb.ie

 

 

10. Date of Revision of the Text

February 2014

June 2012To be inserted upon approval

Updated on 10 March 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 5 July 2012 SmPC

Reasons for updating

  • Change to paediatric information
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 has been updated with regards to the paediatric information.
Section 5.1 has had paediatric information added.
The date of revision has been updated.

Updated on 4 July 2012 PIL

Reasons for updating

  • Change to further information section

Updated on 20 June 2012 PIL

Reasons for updating

  • Change to date of revision
  • Change to dosage and administration

Updated on 12 January 2012 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

New printing ink containing Iron oxide black (E172), Shellac & Propylene Glycol (E1520)

Updated on 12 September 2011 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Update to SPC sections following IMB approval of Company Core Data Sheet (CCDS) version 16.

Updated on 24 May 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 5 October 2009 PIL

Reasons for updating

  • Change of manufacturer
  • Change to date of revision

Updated on 22 June 2009 SmPC

Reasons for updating

  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company



  • In section 6.1 ( List of Excipients ), Structure updated to include; Osmotic Blend, Orgainc Coating and Light Protective Coating; Macrogol 4000 was removed and replaced with Macrogol 3350, Iron oxide red ( E172) was removed and replaced with Ferric Oxide, red (E172).
  • In section 10 (Date of Revision of Text) , November 2008 was removed and replaced with May 2009.

Updated on 22 December 2008 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Insertion of "Excipients: Sodium"

Updated on 10 December 2008 PIL

Reasons for updating

  • Change to information about pregnancy or lactation
  • Change to date of revision

Updated on 4 December 2008 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Changes to Section 4.3, 4.4 and 4.6.

Updated on 26 August 2008 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 6 June 2008 PIL

Reasons for updating

  • Change to marketing authorisation holder
  • Change to date of revision

Updated on 31 August 2006 PIL

Reasons for updating

  • Change to instructions about overdose
  • Change to date of revision

Updated on 18 February 2005 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 31 January 2005 PIL

Reasons for updating

  • Change of manufacturer
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision

Updated on 3 November 2004 PIL

Reasons for updating

  • Change of active ingredient
  • Change of manufacturer
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision

Updated on 28 July 2004 PIL

Reasons for updating

  • New PIL for new product